Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Models of antidepressant action
Autore:
Berman, RM; Charney, DS;
Indirizzi:
Connecticut Mental Hlth Ctr, Clin Neurosci Res Unit, New Haven, CT 06519 USA Connecticut Mental Hlth Ctr New Haven CT USA 06519 ew Haven, CT 06519 USA Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA Yale Univ New Haven CT USA 06520 , Dept Psychiat, New Haven, CT 06520 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
, volume: 60, anno: 1999, supplemento:, 14
pagine: 16 - 20
SICI:
0160-6689(1999)60:<16:MOAA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; TRANSCRANIAL MAGNETIC STIMULATION; CORTICOTROPIN-RELEASING FACTOR; DEPRESSED-PATIENTS; MAJOR DEPRESSION; DOUBLE-BLIND; CATECHOLAMINE DEPLETION; MONOAMINE DEPLETION; INDUCED REMISSION; PINDOLOL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Berman, RM Connecticut Mental Hlth Ctr, Clin Neurosci Res Unit, Room 360,34 Pk St, New Haven, CT 06519 USA Connecticut Mental Hlth Ctr Room 360,34 PkSt New Haven CT USA 06519
Citazione:
R.M. Berman e D.S. Charney, "Models of antidepressant action", J CLIN PSY, 60, 1999, pp. 16-20

Abstract

Although immediate pharmacologic targets can be identified for most antidepressant treatments, elucidation of the critical biological mechanisms leading to symptom relief has defied decades of research. Tn this review, selected neurotransmitter, biochemical, and anatomic models of antidepressant action are considered with regard to their explanatory power and therapeutic applicability. Monoamine models have been a focus of research attention on antidepressant action, an appropriate emphasis in that virtually ail antidepressant medications have high affinity for monoamine substrates. Furthermore, prevailing monoamine models have suggested some promising therapeutic strategies. Nevertheless, these models are ultimately incomplete and do not fully explain important clinical limitations of current treatment: delayed response, incomplete efficacy, and unsustained remissions. Continued therapeutic advancements will likely require the development of models of antidepressant action that extend beyond the monoamines.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:25:00